Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006021 · ClinicalTrials.gov registry record · Phase 1
Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma
A Phase 1 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by University of Miami.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 4
- Study locations
NCT00006021: Completed Phase 1 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by University of Miami.
NCT00006021 is a Phase 1 study of Multiple Myeloma and Plasma Cell Neoplasm that has completed, run by University of Miami. The registered enrollment target is 22 participants, below the 769-participant average among 26 other Multiple Myeloma and Plasma Cell Neoplasm trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006021, a Phase 1 study of Multiple Myeloma and Plasma Cell Neoplasm, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 4
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Vitamin C may increase the effectiveness of arsenic trioxide by making cancer cells more sensitive to the drug. PURPOSE: Phase I/II trial to determine the effectiveness of arsenic trioxide plus vitamin C in treating patients who have recurrent or refractory multiple myeloma.
Conditions Studied
Interventions
- DRUG arsenic trioxide
- DIETARY_SUPPLEMENT ascorbic acid
Study Locations (4)
Florida
- Cedars Medical Center - Miami
- University of Miami Sylvester Comprehensive Cancer Center - Miami
- Baptist-South Miami Regional Cancer Program - Miami
- Mount Sinai Comprehensive Cancer Center at Mount Sinai Medical Center - Miami Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2000-06 |
| Est. Completion | 2007-03 |
| Phase | Phase 1 |
What the finished NCT00006021 record still lists
NCT00006021 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 769-participant average among 26 other Multiple Myeloma and Plasma Cell Neoplasm trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Multiple Myeloma and Plasma Cell Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which arsenic trioxide is the first listed.
NCT00006021 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00006021 about?
NCT00006021 is a clinical study titled "Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Vitamin C may increase the effectiveness of arsenic trioxide by making cancer cells more sensitive to the drug. PURPOSE: Phase I/II trial to determine the effectiveness of arseni...
What is the current status of trial NCT00006021?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2000-06. Estimated completion is 2007-03.
What conditions does trial NCT00006021 study?
This clinical trial studies the following conditions: Multiple Myeloma and Plasma Cell Neoplasm.
What interventions are being tested in trial NCT00006021?
The interventions under investigation include: arsenic trioxide (DRUG), ascorbic acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00006021?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006021 being conducted?
This trial has 4 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma and Plasma Cell Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00006021's enrollment target sits among peer trials
22 21st of 26 higher than 6 of 26 other Multiple Myeloma and Plasma Cell Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma and Plasma Cell Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
COMPLETED · Phase 1
-
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
COMPLETED · Phase 1
-
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
COMPLETED · Phase 1
-
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
COMPLETED · Phase 1
-
Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
COMPLETED · Phase 1
-
Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia